相关实验视频
Updated: Jan 28, 2026

08:52
Author Spotlight: Direct Infusion Device for Molecule Delivery in Plants
Published on: June 2, 2023
3.0K
通过纳米纤维的生物活性分子的向性肝脏输送:最近的发展和新兴方向
Alessia Rita Canestrale1, Sharad Kholia2, Veronica Dimuccio3
1Department of Medical Sciences, University of Torino, 10126 Turin, Italy.
Journal of personalized medicine
|January 27, 2026
概括
脂质纳米颗粒 (LNP),细胞外囊泡 (EV) 和脂质体在肝病治疗中显示有望用于向药物和基因传递. 需要进一步的研究来优化临床使用的稳定性和可扩展性.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 肝病学 肝病学是一种肝病学.
背景情况:
- 肝脏疾病是一个重大的全球健康挑战,治疗选择有限,毒性高.
- 目前用于肝脏疾病的治疗方法通常会导致全身副作用.
- 基于纳米纤维的系统为向药物和基因输送提供了一个有希望的途径,以提高治疗精度.
研究的目的:
- 审查和比较脂质纳米颗粒 (LNP),细胞外囊泡 (EV) 和脂质体在治疗肝脏疾病中的药物和基因传递潜力.
- 在临床前和临床研究中评估这三个纳米纤维平台的优势和局限性.
- 确定未来发展的关键领域,以加强临床翻译.
主要方法:
- 在电子数据库中进行了系统的文献搜索,以寻找肝脏药物或基因输送中的LNP,EV和脂质体的研究.
- 包括专注于临床前和临床研究的研究.
- 分析的数据包括囊泡特征,准效率,有效载荷能力,治疗结果和限制.
主要成果:
- 脂质纳米粒子 (LNP) 显示出高核酸输送效率,并正在向临床应用取得进展.
- 细胞外囊泡 (EVs) 具有良好的生物相容性和自然向肝细胞,但面临生产和标准化障碍.
- 脂质体是多功能载体,但可以通过从循环中快速清除来限制.
结论:
- 脂质纳米颗粒,细胞外囊泡和脂质体是强大的纳米囊泡平台,用于推进肝脏疾病的向治疗.
- 优化纳米纤维稳定性,制造可扩展性和细胞特异性向对于成功的临床转化至关重要.
- 这些纳米载体具有显著的潜力,可以改善各种肝病患者的治疗结果.
更多相关视频
相关概念视频
Emerging Adulthood
656
Jeffrey Arnett's concept of emerging adulthood offers a framework to understand the unique developmental stage between adolescence and full-fledged adulthood, generally from ages 18 to 25. This period is marked by extensive exploration and shifts in identity, relationships, and career choices, a process known in psychology as role experimentation. Emerging adulthood reflects the evolving cultural expectations surrounding adulthood and the dynamic process of personal transformation during...
656
Introduction Cardiac Emergencies
321
Cardiac emergencies are critical situations involving the heart that require immediate medical intervention to prevent severe complications or death. These emergencies often arise from underlying heart conditions that impair the heart's ability to function correctly.Types of Cardiac EmergenciesThe most common types of cardiac emergencies include Acute Coronary Syndrome (ACS), myocardial infarction (MI), cardiac arrest, and heart failure.Acute Coronary Syndrome (ACS)Acute Coronary Syndrome (ACS)...
321
Molecules and Compounds
68.5K
Atoms and Molecules
68.5K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
269
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
269
Hepatic Portal System
5.7K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.7K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
224
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
224

